Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared?

Frontiers in Cell and Developmental Biology

Cell and Developmental Biology

Krzysztof Bryniarski¹  Martyna Cieślik¹  Katarzyna Nazimek² 

[1] Department of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland;null;

关键词: cell-free therapeutics;    dendritic cells;    exosomes;    extracellular vesicles;    immunotherapy;    macrophages;    monocytes;    mononuclear phagocyte system;   

DOI  :  10.3389/fcell.2023.1211833

 received in 2023-04-25, accepted in 2023-06-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

At present, extracellular vesicles (EVs) are considered key candidates for cell-free therapies, including treatment of allergic and autoimmune diseases. However, their therapeutic effectiveness, dependent on proper targeting to the desired cells, is significantly limited due to the reduced bioavailability resulting from their rapid clearance by the cells of the mononuclear phagocyte system (MPS). Thus, developing strategies to avoid EV elimination is essential when applying them in clinical practice. On the other hand, malfunctioning MPS contributes to various immune-related pathologies. Therapeutic reversal of these effects with EVs would be beneficial and could be achieved, for example, by modulating the macrophage phenotype or regulating antigen presentation by dendritic cells. Additionally, intended targeting of EVs to MPS macrophages for replication and repackaging of their molecules into new vesicle subtype can allow for their specific targeting to appropriate populations of acceptor cells. Herein, we briefly discuss the under-explored aspects of the MPS-EV interactions that undoubtedly require further research in order to accelerate the therapeutic use of EVs.

【 授权许可】

Unknown   
Copyright © 2023 Cieślik, Bryniarski and Nazimek.